...
首页> 外文期刊>Journal of inherited metabolic disease >Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria.
【24h】

Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria.

机译:新型模块化蛋白质替代品在苯丙酮尿症饮食治疗中的可接受性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The major source of protein in the dietary treatment of phenylketonuria(PKU) is a phenylalanine-free amino acid mixture. Traditionally, these medical products have also contained other nutrients and have been in powder form. However, their disagreeable taste and odour, the large volume required to provide sufficient protein and the inconvenience of their preparation and storage have hindered compliance with consumption among adolescents and adults. We studied the acceptability of a new medical product for the treatment of PKU. This product, Phlexy-10 (SHS North America, Gaithersburg, MD, USA), is available in three forms: sachets of premeasured powder to be constituted as a drink, fruit-flavoured bars and prefilled capsules. A vitamin-mineral mixture is separately provided. The forms are interchangeable because each component (one sachet, one bar or 20 capsules) provides 10g of amino acids. Since the product is primarily a source of amino acids, protein requirements can be met using a smaller volume than with traditional medical products. Eleven subjects enrolled in a 24-week trial that included clinical and laboratory evaluations. Nine subjects completed the study and 8 remained on the Phlexy-10 after the study. The powder drink was the favourite module used. One-third of the subjects included the bars and another third included the capsules in their regimens. The vitamin-mineral mixture was the least acceptable component. Mean weekly blood phenylalanine decreased by 40% from mean baseline levels. Blood concentrations of vitamins and minerals were normal except for a low zinc concentration in two subjects and a low vitamin B12 concentration in another. The lower caloric content and the separate vitamin-mineral mixture require careful monitoring of these nutrients. Phlexy-10 appears to be an adequate medical product for the treatment of PKU. Its convenience, flexibility of form and improved taste are appealing to many individuals on diet for PKU.
机译:饮食中苯丙酮尿症(PKU)的主要蛋白质来源是不含苯丙氨酸的氨基酸混合物。传统上,这些医疗产品还含有其他营养成分,并且呈粉末状。然而,它们令人讨厌的味道和气味,提供足够蛋白质所需的大体积以及其制备和储存的不便阻碍了青少年和成年人食用的依从性。我们研究了治疗PKU的新医疗产品的可接受性。该产品Phlexy-10(SHS北美,美国马里兰州盖瑟斯堡的SHS)有三种形式:预先制成粉末的小袋装成饮料,带有水果味的棒和预装胶囊。维生素矿物质混合物是单独提供的。这些形式是可互换的,因为每种成分(一个小袋,一个棒或20个胶囊)可提供10克氨基酸。由于该产品主要是氨基酸的来源,因此与传统医学产品相比,使用较小体积即可满足蛋白质需求。 11名受试者参加了为期24周的试验,其中包括临床和实验室评估。 9名受试者完成了研究,而8名受试者在研究结束后仍停留在Phlexy-10上。粉末饮料是最受欢迎的模块。三分之一的受试者在其治疗方案中包括了酒吧,另外三分之一包括了胶囊。维生素-矿物质混合物是最不可接受的成分。平均每周血液苯丙氨酸比平均基线水平降低40%。血液中维生素和矿物质的浓度正常,除了两个受试者的锌浓度低,另一个受试者的维生素B12浓度低。较低的卡路里含量和单独的维生素-矿物质混合物需要仔细监控这些营养素。 Phlexy-10似乎是治疗PKU的合适医疗产品。它的方便性,形式的灵活性和改善的口味吸引了许多北大北平饮食人士。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号